This report covers the esophageal cancer market, comprising key marketed and pipeline drugs, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals.
- It is estimated that in 2016, there were 481,200 incident cases of esophageal cancer worldwide, and expects that number to increase to 527,000 incident cases by 2025.
- Incidence is higher in males compared to females, and is highest in the Asia region. Photofrin, a two-step therapy that involves the injection of the photoactive drug followed by drug activation using laser therapy, is the only drug approved by the US Food and Drug Administration for esophageal cancer.
- Half of the industry-sponsored drugs in active clinical development for esophageal cancer are in Phase II. Therapies in mid-to-late-stage development for esophageal cancer focus on a variety of targets. The majority of pipeline drugs in mid-to-late-stage development are administered intravenously, with two drugs being tested in an oral formulation.
- There have been nine licensing agreements involving esophageal cancer drugs during 2013-18. The $509.8m agreement between Immunocore and GlaxoSmithKline to discover ImmTACs against novel targets was the largest deal.
- The distribution of clinical trials across Phase I-IV indicates that the overwhelming majority of trials for esophageal cancer have been in the early and mid-phases of development, with 91.2% of trials in Phase I-II, and only 8.8% in Phase III-IV.
- The US has a substantial lead in the number of esophageal cancer clinical trials globally. The UK leads the major EU markets, while Japan has the top spot in Asia.
- Clinical trial activity in the esophageal cancer space is dominated by completed trials. Sanofi has the highest number of completed clinical trials for esophageal cancer, with 86 completed trials.
Key Topics Covered
- Key Takeaways
- Disease Background
- Marketed Drugs
For more information about this report visit https://www.researchandmarkets.com/research/j2hzpz/esophageal_cancer?w=4